Maverakis Lab @MaverakisLab

Physician-scientist | autoimmunity, cancer immunotherapy, immunogenetics, & glycans. I'm a 🏃🏻‍♂️ but I don't run marathons. https://t.co/2qJmCRIvbU UC Davis, Dept of Dermatology Joined July 2015

Tweets

345
Followers

7K
Following

5K
Likes

1K

Maverakis Lab @MaverakisLab

a year ago

@finchat_io I was thinking the same thing. Crazy

0 0 1 52 0

View Details

ᶠᵃⁿ In-N-Out Burgers @innoutburger_

a year ago

Welcome to California Luka Doncic. In-N-Out is better than Whataburger.

2K 6K 72K 13.3M 1K

View Details

Maverakis Lab @MaverakisLab

a year ago

@endless_frank So painful. Can't believe how stupid the stock market is.

0 0 0 27 0

View Details

Maverakis Lab @MaverakisLab

a year ago

@The_Real_Fly Yeah- It is pretty obvious that this was not generated with only $4-6 million dollars. Can't believe that the stock market is so sensitive to disruptions.

0 0 0 49 0

View Details

Maverakis Lab @MaverakisLab

a year ago

@libsoftiktok I think it was a good question.

0 0 0 9 0

View Details

@libsoftiktok As an employer I don't know how your post can be accurate. To hire someone on an H1B VISA - they must be paid a "prevailing wage", the average wage paid to similarly employed workers in the same occupation and geographic area. This is a requirement. 🤦‍♂️

0 0 0 22 0

View Details

Maverakis Lab @MaverakisLab

a year ago

@elonmusk Some say- the purpose of the H1B VISA is to allow US companies to hire "indentured servants". This is not true. Employers are required to pay H1B employees a "prevailing-wage". Attracting foreign talent = "Brain Drain", which gives the US a competitive advantage.

0 0 0 68 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

You forgot to mention that the experts thought that "2/" would be impossible. So basically he was a "fool" for setting this as a goal. "2/ the investors/owners create a comp package and majority agree that ONLY if you create $X amount of value within 10 yrs, you’ll be compensated $Y"

0 0 0 26 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@n_hatami @HedgeyeHC Also, there sales numbers are skewed by instrument sales, which should decline over time because the main sequencing centers will not need to purchase more Xeniums. It is more of a one time purchase but reagent sales should continue to rise.

1 0 1 39 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@n_hatami @HedgeyeHC I have no idea. The technology is very sound, especially in spatial sequencing. My advice to them - is that they should focus on making a profit.

0 0 1 45 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@HedgeyeHC $TXG The above turned out to be completely accurate. 10X currently has the best technology in this space.

1 0 0 106 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

The slight loss in revenue from lower scRNA-seq is more than made up for by the increase in use of Xenium and Visium. From what I can tell this trend is the same across the country. I have a small biotech company that conducts precision medicine projects for leading pharma companies, including projects involving scRNA-seq and spatial sequencing. We run these technologies in-house. We are a major 10X customer, most likely the largest volume in Northern CA. I don't think shorting 10X is a wise move. Xenium is now the gold-standard platform for spatial sequencing. Maybe sales of the instruments are slowing but the reagents sales should be increasing. The 5K panel is $$$$. Of course the next quarter will be much better as the technology continues to ramp up. I also don't think instrument sales are that important because the main profit will be made from the reagents, which are ridiculously expensive. Summary- I predict reagent sales from this quarter (ending today) will be up but the numbers should be even better next quarter. Instrument sales might be stagnant but those numbers don't contribute much to the company's profit.

1 0 0 104 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@JoyYWu @StanfordMed @StanfordEndo Congratulations

0 0 1 28 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@visegrad24 @SpaceX Amazing

1 0 1 23 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@skoularidou 💪

0 0 1 248 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@wsleal2014 @RoyEntSoc @SutterHealth @united 🙁

0 0 1 67 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

@mekemzeke @KadyMuhammad1 @MJGold @potnoodlenawank Looking forward to the next olympics. Future is bright.

0 0 0 118 0

View Details

Maverakis Lab @MaverakisLab

2 years ago

Well they were confident after setting a world record. Unfortunately, a world record in an event that is new was not an accurate measure of the team's readiness for the finals. Coaches are balancing other factors- e.g. how many races they want their athletes to run and giving championship experience to younger athletes. Sydney Mclaughlin is obviously saving herself for the 400m Hurdle finals. Wish you were back on the track!!